The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications.

Keywords

Stromal cell, Tumor necrosis factor alpha, Biology, Cancer research, Cell adhesion molecule

References

No references recorded for this paper.

Cited by

• Effect of artesunate on inhibiting proliferation and inducing apoptosis of SP2/0 myeloma cells through affecting NFκB p65Peter G. Beninger, Beninger Pg, Pascoe Pl — 2009
• The Clinically Approved Proteasome Inhibitor PS-341 Efficiently Blocks Influenza A Virus and Vesicular Stomatitis Virus Propagation by Establishing an Antiviral StateLuis Carranza, Ángel Melguizo, David Tuesta — 2010
• Multiple myelomaZ. Vitezica — 2001
• Pathogenesis beyond the cancer clone(s) in multiple myeloma.幸江 栗原 — 2015
• Single cell functional analysis of multiple myeloma cell populations correlates with diffusion profiles in static microfluidic coculture systems.María Lidón Montón García — 2016
• Targeting α4 Integrin Containing Complexes in Multiple Myeloma Using PeptidomimeticsMichael F. Emmons — 2012
• The role of the bone marrow microenvironment in multiple myeloma.H. R. De Raeve, Karin Vanderkerken — 2005
• Copper-zinc superoxide dismutase and glucose metabolism as redox targets for bortezomib resistance in multiple myelomaKelley Salem — 2014
• Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers.Paul G. Richardson, Teru Hideshima, Kenneth C. Anderson — 2003
• ROLE DES MEMBRES DE LA FAMILLE BAFF/APRIL DANS LE MYELOME MULTIPLE : IMPLICATIONS PHYSIOPATHOLOGIQUES ET INTERET THERAPEUTIQUEJérôme Moreaux — 2006
• The role of the tumor microenvironment in hematological malignancies and implication for therapy.Jianbiao Zhou — 2005
• Multiple myeloma: the bone marrow microenvironment and its relation to treatmentSimon William Andrews, Saeed Kabrah, Jennifer May — 2013
• Dynamics of tumor progression and therapy response in Il-6 and Myc driven plasma cell malignancyKaylia Duncan — 2013
• IL-3-Mediated Osteoblast Inhibition in Multiple MyelomaLori A. Ehrlich — 2005
• The role of the bone marrow microenvironment in the establishment and progression of multiple myelomaJ. Fowler — 2010
• Molecular Targeting and Signal TransductionRakesh Kumar — 2004
• Combination of Dasatinib and Dexamethasone targets the myeloma plasma cell through its interaction with the bone marrow microenvironmentK. Ramasamy — 2012
• The microenvironment and molecular biology of the multiple myeloma tumor.Miguel Lemaire, Sarah Deleu, Elke De Bruyne — 2011
• Pharmacogenetic studies in multiple myelomaSophie L. Corthals — 2011
• Genetic variations in multiple myeloma I: effect on risk of multiple myelomaAnnette Juul Vangsted, Tobias Wirenfeldt Klausen, Ulla Vogel — 2012

Related papers

• Role for Stromal Heterogeneity in Prostate TumorigenesisMaria A. Kiskowski, Roger S. Jackson, Jheelam Banerjee — 2011
• FGF9 is an autocrine and paracrine prostatic growth factor expressed by prostatic stromal cellsDipak Kumar Giri, Frédéric Ropiquet, Michael Ittmann — 1999
• Abstract P4-04-26: Down-regulation of p16INK4a inhibits miR-146b-5p and modulates IL-6 in breast stromal fibroblastsMysoon M. Al‐Ansari, Abdelilah Aboussekhra — 2015
• 1,4-dihydroxyxanthone modulates the adhesive property of endothelial cells by inhibiting intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin.Babita Madan, Ashok K. Prasad, Virinder S. Parmar — 2004
• The Structure and Function of Cell Adhesion MoleculesBrian T. Cunningham — 1988
• Cadherins and NCAM as potential targets in metal toxicity.Walter C. Prozialeck — 2002
• The molecular structure of cell adhesion molecules.Cyrus Chothia, E. Yvonne Jones — 1997
• Cell adhesion molecules as tumour suppressors.Lora Hedrick, Kathleen R. Cho, Bert Vogelstein — 1993